Evidence map›Paper›PMID 42080134›Full record

ArticleiScience2026

A fully human pan VL9 HLA-E TCRm antibody enables functional dissection of HLA-E biology and checkpoint signaling.

Soroush Ghaffari, Katherine Upchurch-Ange, Gizem Oter, Trivendra Tripathi, Susanne Gimlin, Debra Wawro Weidanz, Jim Middelburg, Thorbald van Hall, Jon A Weidanz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Soroush GhaffariDepartment of Kinesiology, College of Nursing and Health Innovation, The University of Texas at Arlington, Arlington, TX, USA.
Katherine Upchurch-AngeAbexxa Biologics, Inc., Arlington, TX, USA.
Gizem OterAbexxa Biologics, Inc., Arlington, TX, USA.
Trivendra TripathiAbexxa Biologics, Inc., Arlington, TX, USA.
Susanne GimlinAbexxa Biologics, Inc., Arlington, TX, USA.
Debra Wawro WeidanzAbexxa Biologics, Inc., Arlington, TX, USA.
Jim MiddelburgDepartment of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands.
Thorbald van HallDepartment of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands.
Jon A WeidanzDepartment of Kinesiology, College of Nursing and Health Innovation, The University of Texas at Arlington, Arlington, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HLA-E's function as an immune checkpoint in cancer depends on its display of the canonical peptide (VL9), yet direct profiling of these complexes has been stymied by lack of specific reagents. We now introduce ABX002, a fully human TCR-mimic antibody capable of recognizing all tested VL9/HLA-E complexes with high affinity and specificity

Indexed as

biological sciencesimmunology

Identifiers

PMID42080134
PMCPMC13129390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.